← Full daily brief

Mass Tort brief

Shifting Ground for UK Collective Claims

English courts and policymakers carve out a distinct path for mass consumer litigation, balancing funding access with safeguards against speculative claims.

Signalpoint TeamBrief

Mass Tort

The Court of Appeal has lowered the financial barrier for UK consumer litigation — allowing thousands of claimants to sue collectively on a single form.

BackgroundMass litigation in the UK has historically faced significant procedural hurdles, with defendants often attempting to force claimants to file separate, expensive claim forms. Group Litigation Orders (GLOs) are highly complex and costly to secure.

Points
  1. The ruling in Black Horse Limited v Stuart Angel involves allegations against motor finance providers over undisclosed discretionary commission arrangements, making it a pivotal test case for future consumer claims.
  2. The Court held that the convenience test is met where claims share significant common questions of law and fact, allowing lead cases to guide settlements and reduce delays.
  3. The decision allows over 5,000 consumers to pool their claims on a single form, significantly reducing upfront court fees and administrative barriers to entry for low-value claims.

Mass Tort

The UK High Court has greenlit a consolidated group action against Johnson & Johnson — escalating the global talc litigation battle to the London legal market.

BackgroundJohnson & Johnson faces massive, multi-billion dollar mass tort litigation in the United States over allegations that its baby powder caused ovarian cancer and mesothelioma. UK claimant firms have spent years building parallel collective actions.

Points
  1. The lawsuit alleges that J&J's talc-based baby powder contained asbestos fibers, leading to serious illnesses in long-term UK users, which the company continues to deny.
  2. Mrs Justice Hill and Senior Master Cook ruled that the claims should be managed collectively, scheduling further case management hearings to streamline the litigation process.
  3. The GLO marks a major escalation in UK medical mass tort dockets, bringing US-style product liability pressure to London courts and threatening the company's European market position.

Mass Tort

The UK is introducing class action reforms that expand funding options — while keeping the opt-out regime strictly limited to block speculative US-style lawsuits.

BackgroundThe UK's opt-out collective action regime is currently limited to the Competition Appeal Tribunal. Third-party litigation funders have lobbied for the expansion of this system to other areas of law to make mass claims commercially viable.

Points
  1. The reforms will explicitly permit contingency fees (Damages-Based Agreements) in opt-out claims, expanding alternative funding avenues for complex litigation and lowering financial risks for claimants.
  2. To prevent purely speculative lawsuits, the Competition Appeal Tribunal must assess the reasonableness of a funder's return during certification, creating an extra hurdle for predatory funding.
  3. By keeping opt-out class actions restricted to competition law, the government aimed to protect UK businesses from excessive US-style private litigation that could harm competitiveness.

Unlock the full brief

Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.